8-K: 89bio Reports Fourth Quarter and Full Year 2024 Financial Results, Provides Clinical Trial Updates

89bio announces its Q4 and full year 2024 financial results, highlighting progress in its Phase 3 trials for MASH and SHTG, and provides updates on regulatory feedback and cash position.

Summary

• 89bio reported its financial results for the fourth quarter and full year ended December 31, 2024.
• The company is advancing Phase 3 trials for ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis in MASH, with topline histology data expected in the first half of 2027 and 2028, respectively.
• The Phase 3 ENTRUST trial in SHTG will be unblinded after study completion at Week 52, with topline data now expected in the first quarter of 2026.
• As of December 31, 2024, 89bio had $440.0 million in cash, cash equivalents, and marketable securities.
• A follow-on offering in the first quarter of 2025 resulted in gross proceeds of $287.5 million.
• The company completed enrollment in the Phase 3 ENTRUST trial with 369 patients.
• 89bio obtained regulatory feedback from the FDA and EMA on requirements for marketing authorization filings for pegozafermin.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the company is making progress in its clinical trials and has a strong cash position, the increased net loss and delay in the ENTRUST trial readout temper the positive aspects.

Positives

• 89bio has a strong cash position of $440.0 million as of December 31, 2024, further bolstered by a $287.5 million follow-on offering in 1Q 2025.
• The company is making progress in its Phase 3 trials for MASH, with anticipated topline data in 2027 and 2028.
• Enrollment is complete in the Phase 3 ENTRUST trial for SHTG.
• 89bio has received regulatory feedback from the FDA and EMA, keeping them on track for potential BLA and MAA filings.

Negatives

• The topline data readout for the ENTRUST trial in SHTG has been delayed to Q1 2026 due to a change in the unblinding timeline.
• The company reported a significant net loss of $367.1 million for the year ended December 31, 2024, primarily due to increased R&D expenses.
• Cash reserves decreased from $578.9 million at the end of 2023 to $440.0 million at the end of 2024.

Risks

• The timing and outcome of the ENLIGHTEN-Fibrosis, ENLIGHTEN-Cirrhosis, and ENTRUST Phase 3 trials are uncertain.
• Positive results from clinical studies may not be predictive of future results.
• 89bio is heavily dependent on the success of its lead product candidate, pegozafermin.
• Competition from other companies developing treatments for MASH and SHTG poses a risk.
• The company's ability to raise additional capital is subject to market conditions and other factors.

Future Outlook

89bio anticipates executing on its clinical trials and completing scale-up and regulatory activities to position itself for a successful BLA filing, pending positive results in the Phase 3 trials.

Management Comments

• Rohan Palekar, CEO of 89bio, stated that 2024 was a tremendous year of execution and progress, highlighted by the initiation of two global pivotal trials targeting advanced MASH patients and completion of enrollment in the Phase 3 ENTRUST trial in SHTG.
• Palekar believes pegozafermin has the potential to significantly impact the lives of patients suffering from advanced MASH and SHTG due to its robust fibrosis benefit, potential best-in-class tolerability and safety profile, and convenient dosing.

Industry Context

89bio is focused on developing therapies for liver and cardiometabolic diseases, specifically MASH and SHTG, which are areas of significant unmet medical need. The company's progress in Phase 3 trials and regulatory interactions positions it to potentially compete with other companies developing treatments for these conditions.

Comparison to Industry Standards

• The development of pegozafermin, a FGF21 analog, places 89bio in competition with companies like Akero Therapeutics (efruxifermin) and Viking Therapeutics (VK2809), which are also developing FGF21 analogs for MASH.
• The ENTRUST trial in SHTG aims to demonstrate a significant reduction in triglycerides, a common endpoint in trials for hypertriglyceridemia, similar to studies conducted by Amarin Corporation with Vascepa.
• The ENLIGHTEN trials are designed to meet regulatory requirements for accelerated approval in the US and conditional approval in Europe, similar to strategies employed by other companies in the MASH space, such as Intercept Pharmaceuticals (obeticholic acid).

Stakeholder Impact

• Shareholders: The financial results and clinical trial updates will impact shareholder value and investment decisions.
• Employees: The company's progress and financial stability affect employee morale and job security.
• Patients: The development of pegozafermin has the potential to provide new treatment options for patients with MASH and SHTG.
• Investors: The company's financial performance and clinical trial outcomes will influence investor confidence and future funding opportunities.

Next Steps

• Continue execution of Phase 3 clinical trials for ENLIGHTEN-Fibrosis, ENLIGHTEN-Cirrhosis, and ENTRUST.
• Complete scale-up and regulatory activities to prepare for potential BLA filing.
• Report topline data from ENTRUST trial in 1Q 2026.
• Report topline histology data from ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis trials in 1H 2027 and 2028, respectively.

Key Dates